{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:44:32Z","timestamp":1790073872486,"version":"4.0.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003970","name":"Isfahan University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003970","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","award":["25160"],"award-info":[{"award-number":["25160"]}],"id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ijrobp.2025.05.014","type":"journal-article","created":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T17:54:25Z","timestamp":1747590865000},"page":"891-908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Machine Learning-based Dose Prediction in [177Lu]Lu-PSMA-617 Therapy by Integrating Biomarkers and Radiomic Features from [68Ga]Ga-PSMA-11 Positron Emission Tomography\/Computed Tomography"],"prefix":"10.1016","volume":"123","author":[{"given":"Elmira","family":"Yazdani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5055-4544","authenticated-orcid":false,"given":"Mahdi","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najme","family":"Karamzade-Ziarati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parmida","family":"Jabari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payam","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habibeh","family":"Vosoughi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malihe Shahbazi","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahboobeh","family":"Asadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed Reza","family":"Kheradpisheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parham","family":"Geramifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.05.014_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0002","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.eururo.2016.01.030","article-title":"Remembering Charles B. Huggins\u2019 nobel prize for hormonal treatment of prostatic cancer at its 50th anniversary","volume":"69","author":"Hansson","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0003","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41391-018-0078-1","article-title":"Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies","volume":"22","author":"Alpajaro","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0004","article-title":"Metastatic castration-resistant prostate cancer: academic insights and perspectives through bibliometric analysis","volume":"99","author":"He","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0005","article-title":"Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer","volume":"10","author":"Chen","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0006","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.eururo.2018.03.030","article-title":"Impact of 68Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis","volume":"74","author":"Han","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0007","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.3390\/cancers13153904","article-title":"PSMA theranostics: science and practice","volume":"13","author":"Mokoala","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0008","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.7150\/thno.19782","article-title":"Quantitative imaging for targeted radionuclide therapy dosimetry-technical review","volume":"7","author":"Li","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0009","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-3-319-99286-0_2","article-title":"Advances in radiotherapy for prostate cancer treatment","volume":"1096","author":"Podder","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0010","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.2967\/jnumed.121.262305","article-title":"Dosimetry in radiopharmaceutical therapy","volume":"63","author":"O\u2019Donoghue","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0011","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.18632\/oncotarget.12240","article-title":"Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer","volume":"8","author":"Fendler","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0012","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.2967\/jnumed.124.267452","article-title":"Dosimetry of [177Lu] Lu-PSMA\u2013targeted radiopharmaceutical therapies in patients with prostate cancer: a comparative systematic review and metaanalysis","volume":"65","author":"Ells","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0013","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","article-title":"EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor-and PSMA-targeting ligands","volume":"49","author":"Sj\u00f6green Gleisner","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/14736691211060117","article-title":"ICRU REPORT 96, dosimetry-guided radiopharmaceutical therapy","volume":"21","author":"Sgouros","year":"2021","journal-title":"J ICRU"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0015","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2967\/jnumed.118.209387","article-title":"Potential impact of 68Ga-PSMA-11 PET\/CT on prostate cancer definitive radiation therapy planning","volume":"59","author":"Calais","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0016","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.cpet.2018.05.005","article-title":"Radionuclide therapy for bone metastases: utility of scintigraphy and PET imaging for treatment planning","volume":"13","author":"Ahmadzadehfar","year":"2018","journal-title":"PET Clin"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0017","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3390\/diagnostics14020181","article-title":"Radiomics and artificial intelligence in radiotheranostics: a review of applications for radioligands targeting somatostatin receptors and prostate-specific membrane antigens","volume":"14","author":"Yazdani","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0018","first-page":"1","article-title":"68 Ga] Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177 Lu] Lu-PSMA-617 treatment","volume":"50","author":"Peters","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0019","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1007\/s00259-022-05883-w","article-title":"Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with 177Lu-PSMA I&T therapy","volume":"49","author":"Xue","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0020","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2967\/jnumed.118.219352","article-title":"Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes","volume":"60","author":"Violet","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0021","doi-asserted-by":"crossref","first-page":"7222","DOI":"10.1002\/mp.16746","article-title":"A radiomic-and dosiomic-based machine learning regression model for pretreatment planning in 177Lu-DOTATATE therapy","volume":"50","author":"Plachouris","year":"2023","journal-title":"Med Phys"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0022","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/RLU.0000000000004599","article-title":"177Lu-DOTATATE Theranostics: predicting renal dosimetry from pretherapy: 68: Ga-DOTATATE PET and clinical biomarkers","volume":"48","author":"Peterson","year":"2023","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0023","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1007\/s00259-023-06252-x","article-title":"The predictive value of pretherapy [68Ga] Ga-DOTA-TATE PET and biomarkers in [177Lu] Lu-PRRT tumor dosimetry","volume":"50","author":"Akhavanallaf","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0024","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","article-title":"Radiomics: the bridge between medical imaging and personalized medicine","volume":"14","author":"Lambin","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0025","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s13139-017-0500-y","article-title":"Radiomics in oncological PET\/CT: clinical applications","volume":"52","author":"Lee","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0026","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cpet.2021.06.007","article-title":"Radiomics in PET imaging: a practical guide for newcomers","volume":"16","author":"Orlhac","year":"2021","journal-title":"PET Clin"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0027","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3390\/diagnostics11030428","article-title":"Correlation of an index-lesion-based SPECT dosimetry method with mean tumor dose and clinical outcome after 177Lu-PSMA-617 radioligand therapy","volume":"11","author":"V\u00f6lter","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0028","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2967\/jnumed.115.159012","article-title":"Sj\u00f6green-Gleisner K. MIRD pamphlet no. 26: joint EANM\/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy","volume":"57","author":"Ljungberg","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0029","doi-asserted-by":"crossref","first-page":"36S","DOI":"10.2967\/jnumed.121.262748","article-title":"An international study of factors affecting variability of dosimetry calculations, part 1: design and early results of the SNMMI dosimetry challenge","volume":"62","author":"Uribe","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0030","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40658-016-0148-1","article-title":"Organ-specific SPECT activity calibration using 3D printed phantoms for molecular radiotherapy dosimetry","volume":"3","author":"Robinson","year":"2016","journal-title":"EJNMMI Phys"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0031","doi-asserted-by":"crossref","first-page":"616","DOI":"10.2967\/jnumed.117.200170","article-title":"Optimizing image quantification for 177Lu SPECT\/CT based on a 3D printed 2-compartment kidney phantom","volume":"59","author":"Tran-Gia","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fnume.2023.1291253","article-title":"Quantitative imaging for 177Lu-PSMA treatment response monitoring and dosimetry","volume":"3","author":"Meyer","year":"2023","journal-title":"Front Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0033","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s00259-021-05471-4","article-title":"Intra-therapeutic dosimetry of [177 Lu] Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome","volume":"49","author":"Peters","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0034","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","article-title":"Dosimetry for 177 Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer","volume":"43","author":"Delker","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.apradiso.2024.111378","article-title":"A step toward simplified dosimetry of radiopharmaceutical therapy via SPECT frame duration reduction","volume":"210","author":"Yazdani","year":"2024","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0036","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1080\/09553002.2024.2404448","article-title":"Personalized dosimetry assessment of [177Lu] Lu-PSMA-617 radioligand therapy in the management of metastatic castration-resistant prostate cancer","volume":"100","author":"Kazemi-Jahromi","year":"2024","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0037","first-page":"37S","article-title":"MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates","volume":"40","author":"Siegel","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0038","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.2967\/jnumed.111.100123","article-title":"MIRD pamphlet no. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy","volume":"53","author":"Dewaraja","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0039","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1002\/mp.14243","article-title":"Technical note: rapid multiexponential curve fitting algorithm for voxel-based targeted radionuclide dosimetry","volume":"47","author":"Jackson","year":"2020","journal-title":"Med Phys"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0040","doi-asserted-by":"crossref","DOI":"10.1118\/1.4871617","article-title":"A review of the use and potential of the GATE Monte Carlo simulation code for radiation therapy and dosimetry applications","volume":"41","author":"Sarrut","year":"2014","journal-title":"Med Phys"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0041","first-page":"287","article-title":"IBSI: an international community radiomics standardization initiative","volume":"59","author":"Hatt","year":"2018","journal-title":"Soc Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0042","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","article-title":"LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity","volume":"78","author":"Nioche","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0043","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1007\/s00259-024-06737-3","article-title":"Pre-therapy PET-based voxel-wise dosimetry prediction by characterizing intra-organ heterogeneity in PSMA-directed radiopharmaceutical theranostics","volume":"51","author":"Xue","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0044","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1109\/TRPMS.2024.3381849","article-title":"PBPK-adapted deep learning for pre-therapy prediction of voxel-wise dosimetry: in-silico proof-of-concept","volume":"8","author":"Kassar","year":"2024","journal-title":"IEEE Trans Radiat Plasma Med Sci"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0045","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1097\/RLU.0b013e31823926e5","article-title":"Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?","volume":"37","author":"Ezziddin","year":"2012","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0046","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.zemedi.2013.03.005","article-title":"Treatment planning in molecular radiotherapy","volume":"23","author":"Glatting","year":"2013","journal-title":"Z Med Phys"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0047","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","article-title":"Tolerance of normal tissue to therapeutic irradiation","volume":"21","author":"Emami","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0048","first-page":"939","article-title":"Why we should move beyond the 23 Gray limit for kidney absorbed dose","volume":"64","author":"Brosch-Lenz","year":"2023","journal-title":"Soc Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0049","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1200\/JCO.23.01241","article-title":"How can radiopharmaceutical therapies reach their full potential? Improving dose reporting and phase I clinical trial design","volume":"42","author":"Kiess","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2967\/jnumed.112.107524","article-title":"Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment","volume":"54","author":"Sandstr\u00f6m","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0051","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/0284186X.2011.618511","article-title":"Minor changes in effective half-life during fractionated 177Lu-octreotate therapy","volume":"51","author":"Garske","year":"2012","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0052","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2967\/jnumed.123.265448","article-title":"Renal and multiorgan safety of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer in the VISION dosimetry substudy","volume":"65","author":"Herrmann","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0053","first-page":"1","article-title":"Anemia in men with advanced prostate cancer: incidence, etiology, and treatment","volume":"6","author":"Nalesnik","year":"2004","journal-title":"Rev Urol"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0054","article-title":"Anemia and hypoxia impact on chronic kidney disease onset and progression: review and updates","volume":"15","author":"Habas Sr","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0055","doi-asserted-by":"crossref","first-page":"55094","DOI":"10.18632\/oncotarget.19049","article-title":"Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer","volume":"8","author":"Gaertner","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0056","first-page":"324","article-title":"Association between prostate-specific antigen change over time and prostate cancer recurrence risk: a joint model","volume":"11","author":"Mohammadpour","year":"2020","journal-title":"Caspian J Intern Med"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0057","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0360-3016(97)00082-5","article-title":"Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy","volume":"38","author":"Sartor","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0058","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.humpath.2006.11.012","article-title":"Prostate-specific membrane antigen expression as a predictor of prostate cancer progression","volume":"38","author":"Perner","year":"2007","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0059","first-page":"907","article-title":"Osteomimicry: how tumor cells try to deceive the bone","volume":"2","author":"Rucci","year":"2010","journal-title":"Front Biosci (Schol Ed)"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0060","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.2217\/fon-2018-0087","article-title":"Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker","volume":"14","author":"Heinrich","year":"2018","journal-title":"Future Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0061","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","article-title":"Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer","volume":"75","author":"Heck","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0062","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.2147\/CMAR.S174237","article-title":"Prognostic value of serum alkaline phosphatase in the survival of prostate cancer: evidence from a meta-analysis","volume":"10","author":"Li","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0063","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40644-024-00675-x","article-title":"Automated segmentation of lesions and organs at risk on [68Ga] Ga-PSMA-11 PET\/CT images using self-supervised learning with Swin UNETR","volume":"24","author":"Yazdani","year":"2024","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0064","first-page":"1410","article-title":"Automated deep segmentation of healthy organs in PSMA PET\/CT images","volume":"62","author":"Klyuzhin","year":"2021","journal-title":"Soc Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0065","first-page":"3074","article-title":"Semiautomatic segmentation of metastatic tumor load for 177Lu-PSMA therapy","volume":"63","author":"Parhi","year":"2022","journal-title":"Soc Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0066","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.2967\/jnumed.122.265094","article-title":"An international study of factors affecting variability of dosimetry calculations, part 2: overall variabilities in absorbed dose","volume":"64","author":"Brosch-Lenz","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0067","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2967\/jnumed.117.193706","article-title":"Dose mapping after endoradiotherapy with 177Lu-DOTATATE\/DOTATOC by a single measurement after 4 days","volume":"59","author":"H\u00e4nscheid","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0068","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2967\/jnumed.122.264594","article-title":"Toward single-time-point image-based dosimetry of 177Lu-PSMA-617 Therapy","volume":"64","author":"Brosch-Lenz","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0069","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2967\/jnumed.120.254656","article-title":"Feasibility of single-time-point dosimetry for radiopharmaceutical therapies","volume":"62","author":"Hou","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0070","doi-asserted-by":"crossref","first-page":"528","DOI":"10.2967\/jnumed.120.245548","article-title":"Deep-learning generation of synthetic intermediate projections improves 177Lu SPECT images reconstructed with sparsely acquired projections","volume":"62","author":"Ryd\u00e9n","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.05.014_bib0071","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.2967\/jnumed.123.267293","article-title":"An international study of factors affecting variability of dosimetry calculations, part 3: contribution from calculating absorbed dose from time-integrated activity","volume":"65","author":"Brosch-Lenz","year":"2024","journal-title":"J Nucl Med"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625004808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625004808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T17:45:27Z","timestamp":1762019127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625004808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0360301625004808"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.05.014","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Machine Learning-based Dose Prediction in [177Lu]Lu-PSMA-617 Therapy by Integrating Biomarkers and Radiomic Features from [68Ga]Ga-PSMA-11 Positron Emission Tomography\/Computed Tomography","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}